PulsePoint and ZOLL Accelerate Growth of National Emergency AED Registry, Helping More Communities Locate and Use Devices When Seconds Count
The PulsePoint Foundation, a public non-profit 501(c)(3) that builds public safety applications and maintains the National Emergency AED Registry (NEAR), and ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, including automated external defibrillators (AEDs), announces a new initiative, Anyone Can Register.
The Most Comfortable LifeVest® WCD Ever: ZOLL Completes Full U.S. Launch of Next Generation Garment
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced the complete U.S. rollout of its next generation garment for the LifeVest® wearable cardioverter defibrillator (WCD). With continuous innovation and enhancements for patient comfort, this marks the third advancement of the LifeVest garment over the last five years.
New ZOLL Zenix Monitor/Defibrillator Receives FDA Approval
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA).
TPNS Technology Offered Only by ZOLL’s remedē System Listed in Newly Released Guideline for the Treatment of Central Sleep Apnea
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that transvenous phrenic nerve stimulation (TPNS) – the treatment currently available only by the ZOLL remedē® System – is now included in the updated American Academy of Sleep Medicine (AASM) guidelines for treatment of central sleep apnea (CSA).
SCD-PROTECT publication: High SCD risk despite modern GDMT across 19,500+ LifeVest® patients
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, is highlighting the recent European Heart Journal publication of SCD-PROTECT, an independent clinical trial designed to specifically evaluate the risk of sudden cardiac death (SCD) in the early post-MI/CAD and new NICM period with four-pillar guideline-directed medical therapy (GDMT).
Studies Show Significant Unmet Need in Severe Heart Attack Patients and Cost-Effectiveness of SSO2 Therapy
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today the results of two important studies evaluating the economic burden of heart failure resulting from severe heart attack and the long-term cost-effectiveness of SuperSaturated Oxygen (SSO2) Therapy for heart attack treatment. Results from these studies highlight the need for cost-effective therapies that improve quality of life and reduce the long-term economic burden of heart failure. SSO2 Therapy, used immediately after primary percutaneous coronary intervention (PCI), is the only FDA-approved therapy shown to save damaged heart muscle following severe heart attack, defined clinically as an ST-segment elevation myocardial infarction (STEMI).1
ZOLL Announces Closing of Acquisition of Select Vyaire Ventilator Product Lines
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it successfully completed its previously announced acquisition of certain assets of Vyaire Medical’s ventilator business.
ZOLL announces successful bid to acquire ventilator business from Vyaire Medical
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it is the winning bidder in an auction to acquire Vyaire Medical’s ventilator business as part of Vyaire’s Chapter 11 bankruptcy proceedings. Completion of the acquisition is subject to court approval at a sale hearing and dependent on a successful closing that is anticipated to occur in the coming weeks.
Late-breaking Analysis From the remedē® System Pivotal Trial Suggests Favorable Outcomes for Heart Failure (HF) Patients With Central Sleep Apnea Receiving Phrenic Nerve Stimulation
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that a new analysis of data from the remedē® System Pivotal Trial suggests favorable outcomes for heart failure (HF) patients with central sleep apnea (CSA). The analysis was performed post-hoc using a hierarchical endpoint comprised of mortality, HF hospitalization, and health status. The new analysis was presented as a late-breaking clinical trial at the ESC Heart Failure 2024 conference in Lisbon, Portugal by Dr. William T. Abraham, College of Medicine Distinguished Professor, Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, Columbus, Ohio.
ZOLL Receives FDA Clearance and CE Mark to Expand the Thermogard Platform – All-In-One Core and Surface Cooling
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received FDA clearance and CE mark* for a significant upgrade to the versatility of the Thermogard™ Temperature Management System.
ZOLL Reports Recent Data Security Incident
ZOLL is notifying affected individuals of a data security incident that occurred on January 28, 2023. ZOLL confirmed on February 2, 2023 that an unauthorized third party may have obtained access to some individuals’ protected health information. The PHI may have included some individuals’ names, addresses, dates of birth, some Social Security numbers and information that may allow one to infer that the individual used or was considered for use of the ZOLL LifeVest® wearable cardioverter defibrillator (WCD). ZOLL has no indication that the information has been misused. ZOLL is evaluating its security measures. ZOLL is notifying affected individuals by mail. Individuals with questions can contact a dedicated call center at 800-459-5782 Monday through Friday from 8 am to 10 pm CST and Saturday and Sunday from 10 am to 7 pm CST.
First Patient Enrolled in REAL SSO2 Study to Evaluate Clinical Utility and Economic Value of ZOLL TherOx SSO2 Therapy
ZOLL, an Asahi Kasei company, announced today that the first patient has enrolled in the REAL SSO2 post-market observational study to assess the clinical utility and cost-effectiveness of TherOx SuperSaturated Oxygen (SSO2) Therapy compared to PCI alone in standard of care treatment for ST-elevation myocardial infarction (STEMI) patients. The first patient was enrolled by the interventional cardiology team at St. Mary’s Medical Center in West Virginia, led by site investigator Mehiar El-Hamdani, MD and study coordinator Cheryl Kane, RN.
ZOLL Awarded Diagnostic and Interventional Cardiology Catheter Agreement with Premier, Inc. for TherOx SuperSaturated Oxygen Therapy
ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated Oxygen (SSO2) Therapy has been awarded a group purchasing agreement for Diagnostic and Interventional Cardiology Catheters (DIC) with Premier, Inc., effective as of July 1, 2022. The agreement allows Premier hospital members, at their discretion, to take advantage of special pricing and pre-negotiated terms to access SSO2 Therapy for their ST-segment elevation (STEMI) heart attack patients.
ZOLL Selected to Exhibit TherOx SSO2 Therapy at Vizient Innovative Technology Exchange
ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO2) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17 in Dallas.
